Merck and Daiichi began a Phase III study after Merck acquired co-development rights from Daiichi.
2 reports, 2 independent
Updated Aug 28
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck and Daiichi began a Phase III study after Merck acquired co-development rights from Daiichi.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Merck and Daiichi successfully advanced an ADC through co-development, gaining Breakthrough Therapy designation from the FDA and orphan drug status in Europe.Sub-event
Merck acquired co-development rights from Daiichi to begin a Phase III study.1 source
Keep exploring
The entities involved
-
Merck
public company in Indonesia
-
Daiichi
supermarket in Obihiro, Hokkaido, Japan
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ZacksMRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating
- Business WireHERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy BASKING